今日药学

2009, v.19(10) 41-42+45

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Archive) | 高级检索(Advanced Search)

吡格列酮治疗早期糖尿病肾病疗效观察
Clinical Effect of Pioglitazone in Treating Early Diabetic Nephropathy

曾文谊,孙晓玲
ZENG Wen-yi,SUN Xiao-ling(Pharmaceutical Preparation Section of Dongguan People's Hospital

摘要(Abstract):

目的观察吡格列酮治疗2型糖尿病合并早期糖尿病肾病的临床疗效。方法61例2型糖尿病合并早期糖尿病肾病患者随机分为治疗组和对照组。对照组给予基础治疗,治疗组在基础治疗上加用吡格列酮口服。疗程为12周。比较治疗前、后两组血糖(FBG)、尿白蛋白排泄率(UAER)、胰岛素抵抗指数(Homa-IR)、糖化血红蛋白(HbA1c)等指标变化。结果两组治疗后FBG、HbA1c、UAER、Homa-IR与治疗前比较,下降明显,差异有统计学意义(P<0.05);治疗后两组比较,治疗组FBG、HbA1c、UAER、Homa-IR较对照组下降更明显(P<0.05或P<0.01)。结论吡格列酮可以有效调控早期2型糖尿病肾病患者的血糖,改善胰岛素抵抗,减少尿蛋白排泄,保护肾功能。
Objective To observe the clinical effect of pioglitazone in treating type 2 diabetes mellitus(T2DM)combining early diabetic nephropathy(DN).Methods A total of 61 T2DM patients with early DN were randomly divided into treatment group and control group.All patients were received routine medical treatment,and the treat group was also received pioglitazone.The treatment was lasted for 12 weeks.The differences of fasting blood glucose(FBG),urinary albumin excretion rate(UAER),Homa insulin resistance index(Homa-IR),glycosylated hemoglobin(HbA1c)of the two groups before and after treatment was compared.Results After the treatment,the FBG,HbA1c,UAE,and Homa-IR of the two groups decreased obviously than those before the treatment(P<0.05).After treatment the FBG,HbA1c,UAER,and Homa-IR of the treatment group decreased more significantly than those of the control group(P<0.05).Conclusion Pioglitazone can control the FBG of T2DM patients with early DN effectively and decrease urine protein excretion,and can protect the renal function.

关键词(KeyWords): 吡格列酮;早期糖尿病肾病;胰岛素抵抗
pioglitazone;early diabetic nephropathy;insulin resistance

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 曾文谊,孙晓玲
ZENG Wen-yi,SUN Xiao-ling(Pharmaceutical Preparation Section of Dongguan People's Hospital

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享